Empagliflozin improves obesity-related cardiac function by regulating sestrin2-mediated AMPK-mTOR signaling and enhancing the nuclear factor erythroid-2-related factor (Nrf2)–heme oxygenase 1 (HO-1)-mediated oxidative stress response, suggesting antioxidant and anti-inflammatory capabilities [12]. The gene discussed is NFE2L2; the disease is obesity due to melanocortin 4 receptor deficiency.